ALBT
Avalon GloboCare Corp.
Real Estate - Services
Market Cap$379K
5Y Perf.-99.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ALBT vs NKTR vs FATE vs HALO
Revenue, margins, valuation, and 5-year total return — side by side.
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-74.4%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-92.5%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.68B
5Y Perf.+168.6%
ALBT vs NKTR vs FATE vs HALO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALBT | NKTR | FATE | HALO |
|---|---|---|---|---|
| Industry | Real Estate - Services | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $379K | $1.69B | $280M | $7.68B |
| Revenue (TTM) | $1M | $55M | $7M | $1.40B |
| Net Income (TTM) | $-19M | $-164M | $-136M | $317M |
| Gross Margin | 25.7% | 99.6% | — | 81.9% |
| Operating Margin | -5.1% | -237.9% | -22.2% | 58.4% |
| Forward P/E | — | — | — | 8.1x |
| Total Debt | $8M | $149M | $78M | $0.00 |
| Cash & Equiv. | $3M | $15M | $47M | $134M |
ALBT vs NKTR vs FATE vs HALO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALBT
NKTR
FATE
HALO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Avalon GloboCare Co… (ALBT) | 100 | 0.2 | -99.8% |
| Nektar Therapeutics (NKTR) | 100 | 25.6 | -74.4% |
| Fate Therapeutics, … (FATE) | 100 | 7.5 | -92.5% |
| Halozyme Therapeuti… (HALO) | 100 | 268.6 | +168.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALBT vs NKTR vs FATE vs HALO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Nektar Therapeutics is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ALBT
Avalon GloboCare Corp.
The REIT Holding
ALBT plays a supporting role in this comparison — it may shine differently against other peers.
Best for: real estate exposure
NKTR
Nektar Therapeutics
The Momentum Pick
NKTR is the #2 pick in this set and the best alternative if momentum is your priority.
- +8.2% vs ALBT's -88.9%
Best for: momentum
FATE
Fate Therapeutics, Inc.
The Defensive Pick
FATE is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.17, Low D/E 37.6%, current ratio 5.79x
Best for: sleep-well-at-night
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.56
- Rev growth 37.6%, EPS growth -25.4%, 3Y rev CAGR 28.4%
- 5.7% 10Y total return vs FATE's 40.5%
- Beta 0.56, current ratio 4.66x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HALO | 37.6% revenue growth vs FATE's -51.2% |
| Quality / Margins | HALO | 22.7% margin vs FATE's -20.5% |
| Stability / Safety | HALO | Beta 0.56 vs FATE's 2.17 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | NKTR | +8.2% vs ALBT's -88.9% |
| Efficiency (ROA) | HALO | 12.5% ROA vs ALBT's -207.3%, ROIC 73.4% vs -26.6% |
ALBT vs NKTR vs FATE vs HALO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
FY 2023
FY 2025
ALBT vs NKTR vs FATE vs HALO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGFATE
Who Leads Where
HALO leads in 2 of 6 categories
ALBT leads 1 • NKTR leads 1 • FATE leads 0 • 1 tied
Explore the data ↓FATEFate Therapeutics, In…
0leads
NKTRNektar Therapeutics
1leads
ALBTAvalon GloboCare Corp.
1leads
HALOHalozyme Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs ALBTvs NKTRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO4/6
Valuation MetricsMultiples, price ratios, and targets
ALBT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO is the larger business by revenue, generating $1.4B annually — 1000.4x ALBT's $1M. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to FATE's -20.5%. On growth, HALO holds the edge at +51.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $55M | $7M | $1.4B |
| EBITDAEarnings before interest/tax | -$7M | -$130M | -$148M | $945M |
| Net IncomeAfter-tax profit | -$19M | -$164M | -$136M | $317M |
| Free Cash FlowCash after capex | -$5M | -$209M | -$88M | $645M |
| Gross MarginGross profit ÷ Revenue | +25.7% | +99.6% | — | +81.9% |
| Operating MarginEBIT ÷ Revenue | -5.1% | -2.4% | -22.2% | +58.4% |
| Net MarginNet income ÷ Revenue | -13.6% | -3.0% | -20.5% | +22.7% |
| FCF MarginFCF ÷ Revenue | -3.9% | -3.8% | -13.2% | +46.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.4% | -25.3% | -26.4% | +51.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +96.6% | -4.5% | +38.6% | -2.1% |
HALO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
ALBT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Market CapShares × price | $379,329 | $1.7B | $280M | $7.7B |
| Enterprise ValueMkt cap + debt − cash | $5M | $1.8B | $312M | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.05x | -8.57x | -2.11x | 25.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 8.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 1.11x |
| EV / EBITDAEnterprise value multiple | — | — | — | 8.34x |
| Price / SalesMarket cap ÷ Revenue | 0.28x | 30.64x | 42.18x | 5.50x |
| Price / BookPrice ÷ Book value/share | 0.05x | 15.66x | 1.39x | 165.47x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 11.91x |
ALBT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-4 for NKTR. FATE carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTR's 1.66x. On the Piotroski fundamental quality scale (0–9), ALBT scores 7/9 vs FATE's 2/9, reflecting strong financial health.
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -109.2% | -4.0% | -65.8% | +6.5% |
| ROA (TTM)Return on assets | -2.1% | -62.8% | -42.7% | +12.5% |
| ROICReturn on invested capital | -26.6% | -57.2% | -36.5% | +73.4% |
| ROCEReturn on capital employed | -47.1% | -55.7% | -43.1% | +38.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 | 2 | 5 |
| Debt / EquityFinancial leverage | 1.10x | 1.66x | 0.38x | — |
| Net DebtTotal debt minus cash | $5M | $134M | $31M | -$134M |
| Cash & Equiv.Liquid assets | $3M | $15M | $47M | $134M |
| Total DebtShort + long-term debt | $8M | $149M | $78M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -2.02x | -4.74x | — | 46.08x |
HALO leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,704 today (with dividends reinvested), compared to $29 for ALBT. Over the past 12 months, NKTR leads with a +818.2% total return vs ALBT's -88.9%. The 3-year compound annual growth rate (CAGR) favors NKTR at 93.3% vs ALBT's -75.7% — a key indicator of consistent wealth creation.
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -67.6% | +92.0% | +145.5% | -7.3% |
| 1-Year ReturnPast 12 months | -88.9% | +818.2% | +143.0% | -7.1% |
| 3-Year ReturnCumulative with dividends | -98.6% | +621.8% | -55.4% | +115.3% |
| 5-Year ReturnCumulative with dividends | -99.7% | -72.3% | -96.8% | +37.0% |
| 10-Year ReturnCumulative with dividends | -99.6% | -59.1% | +40.5% | +570.7% |
| CAGR (3Y)Annualised 3-year return | -75.7% | +93.3% | -23.6% | +29.1% |
NKTR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FATE and HALO each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than FATE's 2.17 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs ALBT's 8.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.85x | 2.17x | 0.56x |
| 52-Week HighHighest price in past year | $4.74 | $109.00 | $2.46 | $82.22 |
| 52-Week LowLowest price in past year | $0.34 | $7.99 | $0.91 | $47.50 |
| % of 52W HighCurrent price vs 52-week peak | +8.5% | +76.5% | +98.6% | +79.3% |
| RSI (14)Momentum oscillator 0–100 | 42.4 | 53.4 | 81.0 | 52.4 |
| Avg Volume (50D)Average daily shares traded | 8.4M | 991K | 1.9M | 1.4M |
Evenly matched — FATE and HALO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NKTR as "Buy", FATE as "Buy", HALO as "Buy". Consensus price targets imply 1525.5% upside for FATE (target: $40) vs 20.2% for HALO (target: $78).
| Metric | ALBTAvalon GloboCare … | NKTRNektar Therapeuti… | FATEFate Therapeutics… | HALOHalozyme Therapeu… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $132.83 | $39.50 | $78.33 |
| # AnalystsCovering analysts | — | 33 | 31 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALBT leads in 1 (Valuation Metrics). 1 tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 2 of 6 categories
Loading custom metrics...
ALBT vs NKTR vs FATE vs HALO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ALBT or NKTR or FATE or HALO a better buy right now?
For growth investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ALBT or NKTR or FATE or HALO?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +37. 0%, compared to -99. 7% for Avalon GloboCare Corp. (ALBT). Over 10 years, the gap is even starker: HALO returned +570. 7% versus ALBT's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ALBT or NKTR or FATE or HALO?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 56β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 289% more volatile than HALO relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.
04Which is growing faster — ALBT or NKTR or FATE or HALO?
By revenue growth (latest reported year), Halozyme Therapeutics, Inc.
(HALO) is pulling ahead at 37. 6% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc. grew EPS 29. 9% year-over-year, compared to -430. 8% for Avalon GloboCare Corp.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ALBT or NKTR or FATE or HALO?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -22. 2% for FATE. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ALBT or NKTR or FATE or HALO more undervalued right now?
Analyst consensus price targets imply the most upside for FATE: 1525.
5% to $39. 50.
07Which pays a better dividend — ALBT or NKTR or FATE or HALO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ALBT or NKTR or FATE or HALO better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +570. 7%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ALBT and NKTR and FATE and HALO?
These companies operate in different sectors (ALBT (Real Estate) and NKTR (Healthcare) and FATE (Healthcare) and HALO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ALBT is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; HALO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ALBT: 1.4% · NKTR: -25.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.